Research ExplorerPublicationsOlaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and ...

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

Standard

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. / Ludwig, H; Weisel, K; Petrucci, M T; Leleu, X; Cafro, A M; Garderet, L; Leitgeb, C; Foa, R; Greil, R; Yakoub-Agha, I; Zboralski, D; Vauléon, S; Dümmler, T; Beyer, D; Kruschinski, A; Riecke, K; Baumann, M; Engelhardt, M.

In: LEUKEMIA, Vol. 31, No. 4, 04.2017, p. 997-1000.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ludwig, H, Weisel, K, Petrucci, MT, Leleu, X, Cafro, AM, Garderet, L, Leitgeb, C, Foa, R, Greil, R, Yakoub-Agha, I, Zboralski, D, Vauléon, S, Dümmler, T, Beyer, D, Kruschinski, A, Riecke, K, Baumann, M & Engelhardt, M 2017, 'Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study', LEUKEMIA, vol. 31, no. 4, pp. 997-1000. https://doi.org/10.1038/leu.2017.5

APA

Ludwig, H., Weisel, K., Petrucci, M. T., Leleu, X., Cafro, A. M., Garderet, L., Leitgeb, C., Foa, R., Greil, R., Yakoub-Agha, I., Zboralski, D., Vauléon, S., Dümmler, T., Beyer, D., Kruschinski, A., Riecke, K., Baumann, M., & Engelhardt, M. (2017). Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. LEUKEMIA, 31(4), 997-1000. https://doi.org/10.1038/leu.2017.5

Vancouver

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L et al. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. LEUKEMIA. 2017 Apr;31(4):997-1000. https://doi.org/10.1038/leu.2017.5

Bibtex

@article{9732c2a5f66a44ff9c983edafd4ec609,
title = "Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study",
keywords = "Aged, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Chemokine CXCL12, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligoribonucleotides, Proteasome Endopeptidase Complex, Clinical Trial, Phase II, Journal Article",
author = "H Ludwig and K Weisel and Petrucci, {M T} and X Leleu and Cafro, {A M} and L Garderet and C Leitgeb and R Foa and R Greil and I Yakoub-Agha and D Zboralski and S Vaul{\'e}on and T D{\"u}mmler and D Beyer and A Kruschinski and K Riecke and M Baumann and M Engelhardt",
year = "2017",
month = apr,
doi = "10.1038/leu.2017.5",
language = "English",
volume = "31",
pages = "997--1000",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

AU - Ludwig, H

AU - Weisel, K

AU - Petrucci, M T

AU - Leleu, X

AU - Cafro, A M

AU - Garderet, L

AU - Leitgeb, C

AU - Foa, R

AU - Greil, R

AU - Yakoub-Agha, I

AU - Zboralski, D

AU - Vauléon, S

AU - Dümmler, T

AU - Beyer, D

AU - Kruschinski, A

AU - Riecke, K

AU - Baumann, M

AU - Engelhardt, M

PY - 2017/4

Y1 - 2017/4

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bortezomib

KW - Chemokine CXCL12

KW - Dexamethasone

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Oligoribonucleotides

KW - Proteasome Endopeptidase Complex

KW - Clinical Trial, Phase II

KW - Journal Article

U2 - 10.1038/leu.2017.5

DO - 10.1038/leu.2017.5

M3 - SCORING: Journal article

C2 - 28074071

VL - 31

SP - 997

EP - 1000

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 4

ER -